Unveiling Quality of Clinical Trial in China: from Concern to Confirmation
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Unveiling quality of clinical trial in China: from concern to confirmation.
Huang H, Hou Y, Fang H, Xu L, Yu Y, Zhang H Cancer Commun (Lond). 2024; 44(5):576-579.
PMID: 38446523 PMC: 11110953. DOI: 10.1002/cac2.12528.
References
1.
Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y
. Pharmacovigilance in China: Evolution and future challenges. Br J Clin Pharmacol. 2022; 89(2):510-522.
PMC: 10078654.
DOI: 10.1111/bcp.15277.
View
2.
Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H
. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol. 2022; 23(11):e515-e520.
DOI: 10.1016/S1470-2045(22)00483-1.
View
3.
Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L
. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022; 12(12):4365-4377.
PMC: 9764065.
DOI: 10.1016/j.apsb.2022.08.004.
View
4.
Ma Y, Wang Q, Duan Y, Shi Q, Zhang X, Yang K
. Promoting the quality and transparency of health research in China. J Clin Epidemiol. 2022; 152:209-217.
DOI: 10.1016/j.jclinepi.2022.10.004.
View
5.
Cyranoski D
. China cracks down on fake data in drug trials. Nature. 2017; 545(7654):275.
DOI: 10.1038/nature.2017.21977.
View